Gastrointestinal Associates
Welcome,         Profile    Billing    Logout  
 5 Trials 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Williams, Michael
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting
3
160
Europe, Canada, US, RoW
Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride
Takeda, Takeda Development Center Americas, Inc.
Alpha1-Antitrypsin Deficiency
03/27
03/29
TURBT, NCT06111235: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following

Recruiting
3
364
Canada, US
Cretostimogene Grenadenorepvec, CG0070, n-dodecyl-B-D-maltoside, DDM
CG Oncology, Inc.
Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
01/28
01/30
NCT05508568: A Performance Evaluation Study of Arquer's MCM5 Elisa Test (ADXBLADDER) to Aid in the Monitoring of Recurrence in Non-Muscle Invasive Bladder Cancer

Recruiting
N/A
650
US
ADXBLADDER
Arquer Diagnostics Ltd
Bladder Cancer
01/23
04/23
PENS, NCT05081128: Efficacy in iNPH Shunting () Trial

Recruiting
N/A
100
Europe, Canada, US
programmable CSF shunt valve, FDA-approved Certas Plus with Siphonguard
Johns Hopkins University, National Institute of Neurological Disorders and Stroke (NINDS)
Idiopathic Normal Pressure Hydrocephalus (INPH)
05/26
08/27
Kober, Cindy
No trials found

Download Options